Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narmafotinib - Amplia Therapeutics

Next Previous
Drug Profile

Narmafotinib - Amplia Therapeutics

Alternative Names: AMP-945; CTX-0294945

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Therapeutics CRC; Cytopia Inc
  • Developer Amplia Therapeutics
  • Class Acetamides; Amines; Antifibrotics; Antineoplastics; Fluorinated hydrocarbons; Hepatoprotectants; Phenyl ethers; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Fibrosis; Non-alcoholic steatohepatitis; Ovarian cancer
  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 23 Mar 2026 Updated efficacy and adverse events data from the phase I/II ACCENT in Pancreatic cancer trial released by Amplia Therapeutics
  • 09 Mar 2026 Pharmacodynamics data from a preclinical trial in Cancer released by Amplia Therapeutics
  • 30 Jan 2026 Amplia Therapeutics has patent protection for Narmafotinib in USA, Australia, Europe, Japan, India and Australia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top